All News
Pegloticase in Severe Refractory Gout
Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting.
Read ArticleWhat’s new in knee osteoarthritis that matters?
Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.
Read ArticleRheumNow Podcast – ACR 2020 Epilogue (11.20.20)
Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.
Read ArticleWarfarin and End-Stage Osteoarthritis
Dr. David Liew discusses abstract #0934 - "Warfarin Use and Risk of Knee and Hip Replacements" - presented at the 2020 ACR annual meeting.
Read ArticleTen-Year Analysis of Low-Dose Glucocorticoids in early RA
Abstract #1998 by C. Roubille et al from Montpellier, France is a 10-year prospective analysis that looked at the risk of severe outcomes related to very low-dose glucocorticoid in early rheumatoid arthritis from the ESPOIR cohort.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
#BestACR20Tweets RT @KDAO2011 : FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
Links:
Links:
Links:
Links:


